CRTC2

Across TCGA pan-cancer cohorts, CRTC2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of CRTC2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CRTC2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CRTC2 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

HNSC, KIRC, and LIHC are the cancer types where CRTC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CRTC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+1.055	<.001	12	view →
KIRC	Female	All	+0.481	<.001	10	view →
LIHC	Male	All	+1.293	<.001	9	view →
STAD	Male	II,III,IV	+0.940	<.001	9	view →
COAD	Male	IV	+0.828	<.001	9	view →
BLCA	Female	All	+0.799	<.001	7	view →
BRCA	All	II,III,IV	+0.351	<.001	6	view →
ESCA	All	All	+0.931	<.001	5	view →
KIRP	All	II,III,IV	+0.458	.008	5	view →
LUSC	All	All	+0.232	<.001	5	view →
KICH	All	All	−0.691	<.001	4	view →
CHOL	Male	All	+2.320	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

CRTC2–HNSC

Open the HNSC breakdown →